Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Syntaxin-19 is a Qa-SNARE integral membrane protein involved in the machinery of vesicle fusion, characteristic of the syntaxin family. Syntaxins possess a conserved N-terminal Habc regulatory domain, a central SNARE domain essential for complex formation, and a C-terminal transmembrane anchor. The syntaxin protein family orchestrates the specificity and dynamics of membrane fusion involved in trafficking between cellular compartments. Syntaxin-19’s precise subcellular localization, expression pattern, and function remain poorly characterized relative to prominent syntaxin isoforms like Syntaxin-1A/1B and Syntaxin-4, but likely shares core SNARE-mediated fusion mechanisms fundamental to secretion, signaling, and organelle homeostasis. Data for Syntaxin-19 is notably sparse, and most functional, molecular, or therapeutic advances in the SNARE/syntaxin family pertain to other, better-studied isoforms. No conflicting or erroneous information about the existence of STX19 as a gene/protein is apparent, but there is a lack of characterization in both the literature and therapeutic context.
Not applicable; drugs targeting STX19 have not been described.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Syntaxin-19 (STX19).